Biotechnology

OMEGA THERAPEUTICS INC

OMGAQ.US released FY2024 Q3 earnings on November 14 (BJT), actual revenue 2.612 M USD (forecast 1.342 M USD), actual EPS -0.2981 USD

OMGAQ.US released FY2023 9 Months Earnings on November 14 (BJT), with actual revenue of 2.106 M USD and EPS of -1.4427 USD

OMGAQ.US released FY2023 Q3 earnings on November 14 (BJT), actual revenue 831 K USD (forecast 383.33 K USD), actual EPS -0.4034 USD

OMGAQ.US released FY2024 9 Months Earnings on November 14 (BJT), with actual revenue of 7.106 M USD and EPS of -0.9631 USD

OMGAQ.US released FY2024 Semi-Annual Earnings on August 6 (BJT), with actual revenue of 4.494 M USD and EPS of -0.6606 USD

OMGAQ.US released FY2024 Q2 earnings on August 6 (BJT), actual revenue 2.134 M USD (forecast 1.004 M USD), actual EPS -0.2999 USD

OMGAQ.US released FY2023 Q2 earnings on August 6 (BJT), actual revenue 759 K USD (forecast 430 K USD), actual EPS -0.5399 USD

OMGAQ.US released FY2023 Semi-Annual Earnings on August 6, 2024 (BJT) with actual revenue of 1.274 M USD and EPS of -1.0399 USD

OMGAQ.US released FY2024 Q1 earnings on May 6 (BJT), actual revenue 2.36 M USD (forecast 1.164 M USD), actual EPS -0.3649 USD

OMGAQ.US released FY2023 Q1 earnings on May 6 (BJT), actual revenue 516 K USD (forecast 310 K USD), actual EPS -0.4993 USD

OMGAQ.US released FY2022 Q4 earnings on March 28 (BJT), actual revenue 735 K USD (forecast 257.5 K USD), actual EPS -0.6436 USD

OMGAQ.US released FY2023 Q4 earnings on March 28 (BJT), actual revenue 989 K USD (forecast 530 K USD), actual EPS -0.3665 USD

OMGAQ.US released FY2022 Annual Earnings on March 28 (BJT), actual revenue 2.073 M USD (forecast 1.584 M USD), actual EPS -2.1449 USD

OMGAQ.US released FY2023 annual earnings on March 28 (BJT), actual revenue 3.094 M USD (forecast 2.529 M USD), actual EPS -1.8038 USD

Sidus Space

Autozi Internet Tech Global

Haoxin

Creative Media & Community Trust

Hycroft Mining

Equillium

Starfighters Space

Adeia

Velo3D

Unifirst

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap